Given that tumors characterized by high BACH1 levels often arise in patients with NRF2/KEAP1 mutations, targeting BACH1 or its upstream/downstream proteins represents a promising strategy to combat lung cancer metastasis. This evidence concerns the gene BACH1 and lung carcinoma.